IGF-2 Receptor Agonist Ligands for Neurodevelopmental Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Angelman Syndrome and autism spectrum disorders lack effective therapeutic approaches to alleviate symptoms such as developmental delays, speech impairments, motor disorders, and seizures, with no known cure available.
Innovation Solution
Administration of insulin-like growth factor 2 (IGF-2) receptor agonist ligands, specifically IGF-2 or Mannose-6-phosphate (M6P) and their derivatives, which bind to the IGF-2 receptor to reverse behavioral, cognitive, and motor deficits in neurodevelopmental disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Angelman Syndrome and autism, then current standard of care is maintained, but therapeutic efficacy to alleviate symptoms is insufficient
Solution Approach 1:
The patent changes the biochemical parameter by administering IGF-2 receptor agonist ligands (IGF-2 or M6P) to activate the IGF-2 receptor signaling pathway, which is underactive in Angelman Syndrome. This parameter change (receptor activation) leads to improved synaptic function, memory, and motor coordination, thereby resolving the contradiction between maintaining current care standards and achieving therapeutic efficacy.
2Ease of manufacture
If no curative treatment is available, then current medical limitations are accepted, but symptom amelioration remains unachieved
Solution Approach 1:
The invention utilizes the body's existing IGF-2 receptor system by administering agonist ligands that activate endogenous signaling pathways. The IGF-2 receptor is naturally present in the brain, and the treatment harnesses this self-service mechanism to improve synaptic function and reduce symptoms without requiring complex external intervention systems, thereby making treatment both available and effective.
3Reliability
If IGF-2 receptor agonist ligands are administered, then memory and motor function improve, but the mechanism of action requires specific receptor binding
Solution Approach 1:
The patent uses IGF-2 or M6P as intermediary molecules that specifically bind to and activate the IGF-2 receptor. These intermediaries serve as the link between the administered substance and the therapeutic effect, mediating the signal transduction that leads to improved synaptic function, memory, and motor coordination while maintaining the necessary specificity for effective treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of IGF-2 or M6P receptor ligands significantly improves memory, motor function, and reduces repetitive behaviors in Angelman Syndrome mouse models, demonstrating potential therapeutic benefits for neurodevelopmental disorders.
Implementation Method 1
administering to a subject in need of treatment, a composition comprising an insulin-like growth factor 2 (IGF-2 or IGF-II) receptor agonist ligand, which is specific for the IGF-2 receptor
Data Source
AI summary
Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.